Opinion on  Allergan Inc. (AGN)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Allergan Inc.

Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for glaucoma therapy, ocular inflammation, infection, allergy, and chronic dry eye; Botox for the therapeutic and aesthetic indications; skin care products for acne and psoriasis, as well as other prescription and over-the-counter dermatological products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the Lap-Band System and the BIB BioEnterics Intragastric Balloon; and facial aesthetics products. It also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, and medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A. and Syntaxin. The company was founded in 1948 and is headquartered in Irvine, California.